Release date: 2015-03-12 Sequenom has long relied on its non-invasive prenatal diagnosis to drive growth and scale expansion. But today, the company has launched a new product, MaterniT21, which tests pregnant women with cancer. This potential change will allow Sequenom to expand its market reach. The San Diego, Calif.-based company said that MaterniT21 can detect abnormalities in the fetus by detecting peripheral blood samples from pregnant women, and accurately detected 26 abnormal changes in 40 pregnant women. Companies from Sequenom and other prenatal diagnoses such as Natera, Illumina, and Roche use sequencing technology to scan maternal DNA and fetal DNA secreted from the placenta to determine fetal abnormalities, such as Down syndrome. Tumor cells also release their DNA into the blood, and the abnormalities of the corresponding cancer can be identified by detection. Dr. Dirk Van den Boom, chief technology officer at Sequenom, said Sequenom has been collecting data on pregnant women with abnormal lesions and found no false positives. But this test also brings ethical issues, such as Sequenom is considering whether to tell pregnant women MaterniT21 can identify cancer before testing. Van den Boom said that the company has been entangled in how to deal with the results, but still tend to disclose information. Scientists are making progress in the diagnosis of cancer in pregnant women. Researchers at the University of Leuven in Belgium have developed a blood test for pregnant women with Hodgkin's lymphoma. Dr. Diana Bianchi of Tufts University in the United States said that non-invasive prenatal testing represents the largest clinical manifestation of genomic medicine today. Since 2011, more than one million pregnant women have been tested. At the same time, Sequenom will continue to advance its non-invasive prenatal diagnostic technology and use the market to seek funding, which is expected to reach $3.6 billion in 2019 over the next six years. In January, the company will work with Cypher Genomics to develop a non-invasive prenatal diagnostic test using Cypher's advanced genomic imprinting technology. The new tool will screen the DNA associated with fetal subchromosomal variation in the mother's blood to better detect fetal genetic abnormalities. Source: Bio Valley Dried Fruit,Freeze Dried Strawberries,Dehydrated Fruit,Dried Goji Berries Xi'an Gawen Biotechnology Co., Ltd , https://www.seoagolyn.com
Sequenom has long relied on its non-invasive prenatal diagnosis to drive growth and scale expansion. But today, the company has launched a new product, MaterniT21, which tests pregnant women with cancer. This potential change will allow Sequenom to expand its market reach.